GHRP-6 vs GHRP-2 vs Ipamorelin: Which Growth Hormone Releaser Is Best?

Understanding the GHRP Mechanism

All three peptides work through the same primary receptor — GHS-R1a (growth hormone secretagogue receptor type 1a), also known as the ghrelin receptor. When activated, this receptor on anterior pituitary somatotrophs triggers GH release through phospholipase C signaling and intracellular calcium mobilization.

However, the ghrelin receptor is not exclusive to the pituitary. It exists throughout the body:

• Hypothalamus — regulates appetite and energy homeostasis
• Adrenal glands — modulates cortisol release
• Pituitary lactotrophs — influences prolactin secretion
• Stomach — regulates gastric motility and hunger signaling
• Heart and vasculature — cardiovascular effects
• Hippocampus — memory and neuroprotection

This is where the three GHRPs diverge. Their differing molecular structures create different binding affinities and activation profiles across these receptor populations. A peptide that slams the pituitary GHS-R1a also slams the hypothalamic appetite centers and the adrenal cortisol pathway — unless it was specifically designed not to.

---

GHRP-6: The Brute Force Approach

Profile

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was one of the first synthetic GHRPs developed. It is a hexapeptide with broad receptor activation and the strongest appetite stimulation of any GHRP.

GH Release Potency

GHRP-6 produces robust GH release — approximately 3-5x baseline at standard doses. In head-to-head pharmacokinetic studies, it produces slightly more total GH area-under-curve than Ipamorelin but slightly less peak GH than GHRP-2 (Bowers et al., 1991).

The Hunger Problem

GHRP-6's defining characteristic — and either its greatest feature or its deal-breaker depending on your goals — is its extreme ghrelin-mimetic activity. Within 15-20 minutes of injection, users experience intense, almost irresistible hunger that lasts 30-60 minutes.

This is not subtle appetite stimulation. Users describe it as "starving" regardless of recent food intake. The mechanism: GHRP-6 directly activates hypothalamic NPY/AgRP neurons and vagal afferents in the stomach, mimicking the orexigenic signaling of endogenous ghrelin.

For hardgainers struggling to eat enough calories during a bulk, this is a feature. For anyone in a caloric deficit or with binge-eating tendencies, it is a serious problem.

Cortisol and Prolactin

GHRP-6 significantly elevates cortisol (approximately +30-50% acutely) and moderately elevates prolactin. These effects are dose-dependent and most pronounced at doses above 100mcg. While acute cortisol elevation is not inherently harmful, chronic elevated cortisol from 3x daily dosing can promote catabolism, fat storage, and impaired recovery — exactly what you are trying to avoid.

Dosing

• Standard: 100mcg subcutaneous, 2-3 times daily
• Saturation dose: ~1mcg/kg body weight per injection (beyond this, diminishing GH returns)
• Timing: Pre-meal (use the hunger spike productively) or upon waking

Best For

• Bulking phases where appetite is limiting
• Underweight individuals needing caloric surplus
• Short-term GH "blast" cycles (4-8 weeks)
• Users who want maximum GH release regardless of side effects

[Internal Link: /ghrp-6/]

---

GHRP-2: The Middle Ground

Profile

GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) is structurally related to GHRP-6 but with a modified amino acid sequence that shifts its selectivity profile. It retains strong GH-releasing activity while partially attenuating appetite stimulation and hormonal cross-reactivity.

GH Release Potency

GHRP-2 produces the highest peak GH concentrations of the three peptides compared here. Studies show GH spikes of 5-8x baseline at standard doses — marginally exceeding GHRP-6 in peak amplitude (Bowers et al., 1991; Arvat et al., 1997). Total GH AUC (area under curve) is comparable between GHRP-2 and GHRP-6.

Appetite Stimulation

GHRP-2 does increase appetite, but the effect is approximately 50-60% as intense as GHRP-6. Users report a noticeable increase in hunger that is manageable rather than overwhelming. The mechanism is identical (GHS-R1a activation in hypothalamus) but the binding profile is less aggressive at peripheral ghrelin receptor sites.

Cortisol and Prolactin

Here is where GHRP-2 shows its limitations:

• Cortisol elevation: Still significant (~25-40% acutely), though slightly less than GHRP-6
• Prolactin elevation: Moderate and dose-dependent (Bowers, 1998)

The prolactin issue is clinically relevant. Chronic prolactin elevation in men can cause decreased libido, gynecomastia, and impaired testosterone production. While acute post-injection prolactin spikes from GHRP-2 are transient (normalizing within 2-3 hours), the cumulative effect of 2-3 daily injections over months is unclear.

Dosing

• Standard: 100-300mcg subcutaneous, 2-3 times daily
• Optimal for GH/side effect ratio: 100-150mcg per injection
• Timing: Upon waking, post-workout, and before bed (the three natural GH pulse windows)

Best For

• Users wanting maximum GH release with moderate side effect tolerance
• Intermediate approach between raw power and selectivity
• Those who benefit from some appetite stimulation but not GHRP-6 level hunger
• Athletes in maintenance or slight surplus phases

[Internal Link: /ghrp-2/]

---

Ipamorelin: The Selective Scalpel

Profile

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) represents the third generation of GHRP design — engineered specifically for selectivity. It was developed to answer a question: can we get meaningful GH release without activating the cortisol, prolactin, and appetite pathways?

The answer is yes.

GH Release Potency

Ipamorelin produces approximately 3-4x baseline GH elevation at standard doses. This is slightly less than GHRP-2 peak values and comparable to GHRP-6 total output. The difference is clinically modest — perhaps 10-20% less total GH per injection compared to GHRP-2 at equivalent doses (Raun et al., 1998).

The Clean Profile

This is Ipamorelin's defining advantage:

• Cortisol: No significant elevation, even at doses 10x above saturation (Anderson et al., 2001)
• Prolactin: No significant elevation at standard doses
• Appetite: Minimal to no increase in hunger signaling
• ACTH: No elevation (confirming no adrenal axis stimulation)

This selectivity is remarkable and unique among GHRPs. Ipamorelin achieves it through a highly specific binding profile that preferentially activates pituitary somatotroph GHS-R1a while demonstrating minimal activity at hypothalamic and peripheral receptor populations.

Clinical Significance of Selectivity

The practical implication: Ipamorelin can be dosed 2-3 times daily, indefinitely, without:

• Cortisol-driven fat storage or catabolism
• Prolactin-related libido/gynecomastia issues
• Appetite disruption during cutting phases
• Desensitization concerns (Ipamorelin shows minimal receptor downregulation)

This makes it the only GHRP suitable for long-term (6+ month) continuous use without cycling.

Dosing

• Standard: 200-300mcg subcutaneous, 2-3 times daily
• Conservative: 100mcg, 2x daily (anti-aging protocols)
• Aggressive: 300mcg, 3x daily (maximum GH without selectivity loss)
• Timing: Upon waking and before bed (minimum); add post-workout for 3x protocol

Best For

• Long-term anti-aging and wellness optimization
• Cutting phases where appetite control matters
• Users sensitive to cortisol (high-stress lifestyles, adrenal concerns)
• Women (lower prolactin risk, no appetite disruption)
• Anyone prioritizing side-effect-free GH optimization

[Internal Link: /ipamorelin/]

---

Head-to-Head Comparison Table

---

The Critical Stack: Why All Three Need CJC-1295

Here is the single most important protocol insight for any GHRP user: GHRPs work dramatically better when combined with a GHRH analog.

The synergy is not additive — it is multiplicative. GHRP alone might produce a 3-5x GH spike. GHRH alone might produce a 2-3x spike. Together, the same doses produce an 8-12x spike (Bowers et al., 2004). The mechanism: GHRP primes the somatotroph through calcium signaling while GHRH amplifies through cAMP signaling — two distinct intracellular pathways converging on GH secretory granule exocytosis.

Recommended Stack Protocols

GHRP-6 + CJC-1295 (no DAC) — Bulk Stack:

• GHRP-6: 100mcg
• CJC-1295 (mod GRF 1-29): 100mcg
• Combined, 2-3x daily before meals
• 8-12 week cycles

GHRP-2 + CJC-1295 (no DAC) — All-Purpose Stack:

• GHRP-2: 100-150mcg
• CJC-1295 (mod GRF 1-29): 100mcg
• Combined, 2-3x daily
• 12-16 week cycles

Ipamorelin + CJC-1295 (no DAC) — Clean GH Stack:

• Ipamorelin: 200-300mcg
• CJC-1295 (mod GRF 1-29): 100mcg
• Combined, 2-3x daily
• Can run indefinitely (most popular long-term protocol in Canadian clinics)

Ipamorelin + CJC-1295 DAC — Convenience Stack:

• Ipamorelin: 200-300mcg daily (morning)
• CJC-1295 DAC: 2mg once weekly (Monday evening)
• Simple protocol, fewer injections, but less pulsatile GH pattern

[Internal Link: /cjc-1295-dac/] [Internal Link: /cjc-1295-no-dac/]

---

Side Effects: What to Expect With Each

GHRP-6 Side Effects

• Intense hunger (15-60 minutes post-injection) — nearly universal
• Water retention (first 1-2 weeks, usually resolves)
• Tingling/numbness in hands (transient)
• Cortisol-related: potential fat storage if diet not controlled during hunger window
• Head rush/lightheadedness immediately post-injection (rare)
• Potential prolactin-related issues with chronic use (libido, nipple sensitivity)

GHRP-2 Side Effects

• Moderate hunger increase (manageable for most)
• Water retention (first 1-2 weeks)
• Cortisol elevation (less than GHRP-6 but present)
• Prolactin concerns with long-term use
• Occasional tiredness/lethargy 30-60 minutes post-injection
• Head rush post-injection (uncommon)

Ipamorelin Side Effects

• Mild headache (first few days, usually resolves)
• Slight water retention (first week, usually resolves)
• Injection site irritation (standard for any peptide)
• Rare: nausea at higher doses (>400mcg)
• No cortisol, prolactin, or appetite effects at standard doses

The side effect profile alone makes the case for Ipamorelin in most scenarios. The only reason to choose GHRP-6 or GHRP-2 is if you specifically want the appetite stimulation (GHRP-6) or maximum possible GH amplitude (GHRP-2).

---

Decision Framework: Which GHRP Should You Choose?

Choose GHRP-6 If:

• You are in a dedicated bulking phase and struggle to eat enough
• Maximum caloric intake is a priority
• You plan to cycle 8-12 weeks only (not long-term)
• You are lean and do not store fat easily
• You want the "on switch" for appetite when it matters

Choose GHRP-2 If:

• You want maximum GH release and can tolerate moderate sides
• You are in a slight caloric surplus but not aggressively bulking
• You do not have prolactin sensitivity concerns
• 12-16 week cycles fit your plan
• You want a middle ground without strong preference either direction

Choose Ipamorelin If:

• Long-term GH optimization is the goal (anti-aging, wellness, body recomposition)
• You are cutting or maintaining and need zero appetite disruption
• You have high-stress lifestyle or cortisol concerns
• You want indefinite use without cycling
• Clean blood work matters to you
• You are female (lower prolactin risk, no hunger disruption)
• You are over 40 and prioritize safety over maximum potency

The Pragmatic Answer

For 80% of Canadian peptide users, Ipamorelin + CJC-1295 (no DAC) is the correct answer. The slight reduction in GH potency compared to GHRP-2 is more than compensated by:

• No cycling requirement
• No cortisol/prolactin monitoring needed
• No appetite management during cuts
• The longest safety track record
• The cleanest blood work profile

The remaining 20% are dedicated bulkers (GHRP-6) or competitive athletes seeking every fraction of GH output (GHRP-2 for short cycles).

---

Frequently Asked Questions

Can I switch between GHRPs mid-cycle?

Yes. There is no pharmacological reason you cannot transition between GHRPs. A common approach: run GHRP-6 during a 4-week bulk for appetite support, then switch to Ipamorelin for the subsequent cut or maintenance phase. No washout period is needed — the receptor mechanisms are identical, only the selectivity profiles differ.

Do GHRPs show up on drug tests?

GHRPs themselves have short detection windows (hours). However, the abnormal GH and IGF-1 patterns they create can be detected by the GH-2000 biomarker test used by WADA and similar anti-doping agencies. The isoform ratio test (detecting exogenous GH) will be negative, but growth factor biomarker panels may flag abnormalities. All three GHRPs are prohibited by WADA under S2 (Peptide Hormones, Growth Factors).

Is there a maximum dose beyond which GHRPs stop working?

Yes — the saturation dose for all GHRPs is approximately 1mcg per kg of body weight per injection (roughly 100mcg for a 100kg individual). Beyond this, GH response plateaus and side effects increase linearly. Taking 300mcg of GHRP-6 does not produce 3x the GH of 100mcg — it produces approximately the same GH with 3x the hunger and cortisol. The exception is Ipamorelin, which shows a more linear dose-response up to approximately 300mcg before plateauing.

Can women use GHRPs safely?

All three GHRPs are used by women. Ipamorelin is overwhelmingly preferred due to its lack of prolactin elevation (which can disrupt menstrual cycles) and absence of appetite stimulation (which women more commonly report as problematic vs. men). Doses are the same regardless of sex — the saturation dose scales with body weight, not sex hormones.

How long until I see results from GHRPs?

Elevated GH levels occur within the first injection. Body composition changes typically become noticeable at 4-6 weeks: improved sleep quality first (week 1-2), then skin/hair improvements (week 3-4), then visible fat loss and muscle density (week 6-12). For significant body recomposition, commit to a minimum 12-week protocol with consistent diet and training.

---

Conclusion: Selectivity Is Usually Worth More Than Potency

The peptide community has a bias toward "strongest" that does not serve most users. GHRP-6 produces jaw-dropping GH spikes — and jaw-dropping hunger, cortisol, and prolactin alongside them. GHRP-2 hits the highest peak numbers on a blood test — while quietly elevating stress hormones that undermine the very goals you are chasing.

Ipamorelin sacrifices 10-20% of peak GH amplitude to eliminate 100% of the problematic cross-reactivity. For sustained, year-round GH optimization that actually translates to better body composition, better sleep, better recovery, and better aging — selectivity wins every time.

Stack your chosen GHRP with CJC-1295 (no DAC) for synergistic amplification. Run it consistently. Dose at saturation, not above. And pick the peptide that matches your actual goals, not the one with the most impressive single-number GH spike on a forum post.

[Internal Link: /ipamorelin/] [Internal Link: /ghrp-6/] [Internal Link: /ghrp-2/] [Internal Link: /cjc-1295-no-dac/]

---

References:

• Bowers CY, et al. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027-2035.
• Arvat E, et al. (1997). Preliminary evidence for an interaction between GHRP-6 and GHRH in humans. Journal of Endocrinological Investigation, 20(4), 217-224.
• Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
• Anderson LL, et al. (2001). Ipamorelin: selectivity among secretagogues. Endocrine, 14(1), 45-55.
• Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316-1329.
• Bowers CY, et al. (2004). Synergistic release of growth hormone by GHRP and GHRH. Journal of Clinical Endocrinology & Metabolism, 89(11), 5174-5183.